Literature DB >> 16003181

Angiotensin II, type 2 receptor is not involved in the angiotensin II-mediated pro-atherogenic process in ApoE-/- mice.

Maria E Johansson1, Anna Wickman, Sharyn M Fitzgerald, Li-ming Gan, Göran Bergström.   

Abstract

OBJECTIVE: Angiotensin II (Ang II) accelerates atherogenesis in ApoE mice via the angiotensin II, type 1 receptor (AT1) while the type 2 receptor (AT2) is suggested to counteract atherogenesis. To confirm and further explore this possibility, we studied the effect of AT2 receptor antagonism on Ang II-accelerated atherosclerosis.
METHODS: ApoE mice were fed a standard or high cholesterol diet (1.25%) for 4 weeks. Mice on each diet were treated with either Ang II (0.5 microg/kg per min) or Ang II in combination with PD123319 (3 mg/kg per day). Plaque distribution was assessed by en face quantification of the thoracic aorta and in cross-sections of the aortic root. Mean arterial pressure (MAP) was measured. AT1 and AT2 receptor expression were analysed using real-time polymerase chain reaction (PCR) and the localization of the AT2 receptor protein confirmed with immunohistochemistry.
RESULTS: Ang II infusion increased MAP only in mice on a standard diet (P < 0.001). Regardless of diet, Ang II-infused mice had 22-30 times increased plaque area in the thoracic aorta (P < 0.001 for both). Ang II had no effect on plaque in the aortic root. Plaque area was not affected by PD123319. AT2 receptor was heavily expressed in the plaques and increased six- to ninefold by a high cholesterol diet and Ang II infusion (P < 0.01).
CONCLUSION: Ang II increases the extent of atherosclerosis in ApoE mice. Despite up-regulation of the AT2 receptor, we found no support for an effect of the AT2 receptor on atherogenesis in this model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003181     DOI: 10.1097/01.hjh.0000174078.95745.77

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.

Authors:  Hong Lu; Anju Balakrishnan; Deborah A Howatt; Congqing Wu; Richard Charnigo; Gene Liau; Lisa A Cassis; Alan Daugherty
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  The renin-angiotensin system and atherosclerosis.

Authors:  Lucia Mazzolai; Daniel Hayoz
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 3.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

4.  Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.

Authors:  A Koïtka; Z Cao; P Koh; A M D Watson; K C Sourris; L Loufrani; A Soro-Paavonen; T Walther; K J Woollard; K A M Jandeleit-Dahm; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

Review 5.  AT2 receptors: functional relevance in cardiovascular disease.

Authors:  Emma S Jones; Antony Vinh; Claudia A McCarthy; Tracey A Gaspari; Robert E Widdop
Journal:  Pharmacol Ther       Date:  2008-08-31       Impact factor: 12.310

6.  PD123319 augments angiotensin II-induced abdominal aortic aneurysms through an AT2 receptor-independent mechanism.

Authors:  Alan Daugherty; Debra L Rateri; Deborah A Howatt; Richard Charnigo; Lisa A Cassis
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

7.  Metoprolol reduces proinflammatory cytokines and atherosclerosis in ApoE-/- mice.

Authors:  Marcus A Ulleryd; Evelina Bernberg; Li Jin Yang; Göran M L Bergström; Maria E Johansson
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.